International AIDS Conference

The Latest

Mapping the Microbiome: Vaginal Bacteria and HIV Risk

The list of things that increase a person's risk for HIV acquisition are pretty well known: poverty, lack of access to health care, condomless sex with someone who doesn't know they have HIV. But vaginal bacteria? We investigate.

By Heather Boerner

Despite Male Youth's Similar Sexual Behaviors, MSM Have a Significantly Higher Risk of Acquiring HIV

Despite not engaging in notably riskier sexual behavior, gay and bisexual male teens have an elevated risk of acquiring HIV because their sex partners are more likely to have HIV and they are more likely than their peers to inject drugs, according to...

By Rod McCullom

Gay Dating Apps Join HIV Prevention and Treatment Education Efforts

Gay dating apps Grindr, Hornet and Blued recently discussed their efforts to promote PrEP education and HIV testing in a presentation at the International AIDS Conference.

By David Durán

On-Demand PrEP Effective Among MSM, but High Rates of STIs Observed

Taking pre-exposure prophylaxis (PrEP) "on demand," meaning only around the time of sexual intercourse was effective in preventing HIV infection among men who have sex with men (MSM), Jean-Michel Molina, M.D., of the University of Paris Diderot repor...

By Barbara Jungwirth

First Trials of HIV Vaccine Using Broadly Neutralizing Antibodies Begin

The first large-scale human studies for the development of an anti-HIV vaccine using monoclonal antibodies have just begun enrollment. These are passive immunizations using a laboratory-generated antibody that proved to be highly effective in animal ...

By Barbara Jungwirth

Early HIV Treatment Lowers Transmission Risk by Up to 93%: HPTN 052 Final Results

Final results of HPTN 052, the watershed randomized trial that positioned antiretroviral therapy (ART) as an HIV prevention strategy, indicate that participants starting ART at a high CD4 count sustained a 93% lower risk of transmitting HIV to sex pa...

By Mark Mascolini

Consistent Use of Dapivirine Vaginal Ring Could Offer More Than 75% HIV Protection, New Data Suggests

Seventy-five percent: That's how much HIV protection women might be able to expect from a flexible silicone ring loaded with the antiretroviral medicine dapivirine when they put it in their vaginas and leave it there.

By Heather Boerner

Rilpivirine as HIV PrEP Remains in Body 18 Months After Single Long-Acting Shot

Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).

By Mark Mascolini

Maraviroc Fails to Block SIV Infection in Orally Exposed Infant Macaques

Twice-daily oral maraviroc (Selzentry, Celsentri) failed to prevent SIV infection in infant macaques orally exposed to the virus, but the findings do not rule out potential use in human infants.

By Mark Mascolini

Oral Maraviroc PrEP Protects U.S. Women From HIV in 48-Week Study

No woman taking daily maraviroc pre-exposure prophylaxis (PrEP) with or without tenofovir (TDF, Viread) or emtricitabine (FTC, Emtriva) became infected with HIV through 48 weeks in a randomized, double-blind, 188-woman U.S. study.

By Mark Mascolini